Skip to content

IN2PHARMA

Active Public limited companyfounded 2008active for 18 yearsTerloonststraat 22, 1910 KampenhoutKBO/BCE: BE 0895.730.662 subsidiary of

Board

4 directors, 1 in day-to-day management, no change since April 2026
Director
since 02-04-2026 6-year term from 2026
also on the board of 1 other company
listed in the 2025 annual accounts, filed on 22-06-2026
Director
since 02-04-2026 6-year term from 2026
also on the board of 1 other company
listed in the 2025 annual accounts, filed on 22-06-2026
Director
since 02-04-2026 6-year term from 2026
listed in the 2025 annual accounts, filed on 22-06-2026
Director, permanent representative
current term since 13-04-2026
listed in the 2025 annual accounts, filed on 22-06-2026
Day-to-day manager, permanent representative
appointed by deed of 13-05-2026 term without a fixed end
earlier director, from 01-02-2021 to 02-04-2026
earlier managing director, from 30-06-2017 to 02-04-2026
also on the board of 3 other companies
Signing authorityThe articles say who may bind the company, for example by signing a contract.
Two directors jointly, or a managing director alone
deed of 13-05-2026
Permanent representatives 2
Permanent representative, for
appointed by deed of 20-04-2015
Permanent representative, for
appointed by deed of 13-05-2026

Office holders in the KBO →

Mandates through the years

5 names, the dashed line is today

Director

Director

Director

Director

Day-to-day manager
LeadershipBoardEarlierRest of the termmandate already running before its first mention
Mandates as a list
    • Director, appointed by deed of 20-04-2015, still in office
    • Director, since before 31-12-2025
    • Director, since before 31-12-2025
    • Director, since before 31-12-2025
    • Managing director, appointed by deed of 23-10-2017, until 19-06-2024
    • Director, until 30-06-2017
    • Managing director, appointed by deed of 23-10-2017, until 02-04-2026
    • Day-to-day manager, appointed by deed of 13-05-2026, still in office
With Starter you also see 5 former office holders in the mandate history. See the plans →

Control

Parent
Equity €100,896
Profit €896 in 2025
Checked score
100%
This company
IN2PHARMA
Equity €69,300
Profit €909,969 in 2025

Capital

Capital
€63,000
Shares
63,000
Contribution per share
€1
Equity per share
€1.10 in 2025
Source
deed of 19-06-2024

Owners through the years

as the annual accounts name them
66.67%
Owners as a list
    • 2015 to 2018: 67%
    • 2019: 66.66%
    • 2020 to 2023: 66.67%

Source: lists of holdings in the owners' accounts

Articles of association

deed of 19-06-2024 (in Dutch)
DurationMost companies exist for an unlimited period, until they are dissolved.
Unlimited
Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
Last Friday of June at 19:00
Liquidation ruleIn a liquidation the creditors are paid first. What is left goes to the shareholders.
Alle actiefbestanddelen gerealiseerd tenzij anders beslist, artikelen 2:87 en 2:88,algemene vergadering kan beperken

Capital transactions

Shareholders according to the deeds
Stated in the deed deed of 13-05-2026 ↗
  • all shares
Stated in the deed deed of 12-02-2026 ↗
  • all shares
Capital over time
  1. 19-06-2024 Capital stated in the deed · €63,000 · 63,000 shares

Next steps